Factors associated with rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation

• Published in: Clinical transplantation and research 2023, 37(3), , pp.170-178
• Main Authors: Hong, Suk Kyun, Lee, Kwang-Woong, Kim, Jae-Yoon, Lee, Jaewon, Kim, Jiyoung, Choi, Hyun Hwa, Hong, Su young, Lee, Jeong-Moo, Choi, YoungRok, Yi, Nam-Joon, Suh, Kyung-Suk
• Format: Article
• Language: English
• Subjects: liver transplantation; abo blood-group system; rituximab; polymorphism; Original; 의학일반
• ISSN: 2671-8790; 3022-6783; 2671-8804; 3022-7712
• DOI: 10.4285/kjt.23.0031

BackgroundPretransplant therapies such as rituximab and plasmapheresis have led to an increase in ABO-incompatible (ABOi) living donor liver transplantation (LDLT), thus helping to overcome organ shortages. This study evaluated the changes in anti-A/B titers and CD19 levels over time in patients undergoing ABOi LT and aimed to understand the effect of single-nucleotide polymorphisms (SNPs) in Fc gamma receptor (FcγR) on rituximab therapy. MethodsTwo SNPs of FCGR2A (131H/R) and FCGR3A (158F/V) were identified. The clinical data on 44 patients who underwent ABOi LDLT between May 2019 and October 2021 at Seoul National University Hospital were reviewed retrospectively. ResultsFollowing desensitization with rituximab and subsequent LDLT, the anti-A/B titer recovered within 1 week, but decreased thereafter. The CD19 level increased at 3 months after LT. The genotyping data for FCGR3A (158F/V) indicated that two patients had the V/V genotype, and 42 had the F/V genotype. In the genotyping data for FCGR2A (131H/R), 21 patients had the H/H genotype, three had the R/R genotype, and 20 had the H/R genotype. However, there were no significant differences in anti-A/B and CD19 levels, bacteremia rates, T cell-mediated rejection, antibody-mediated rejection, or the survival rate among the FCGR2A types. ConclusionsThere were significant changes in the anti-A/B titers and CD19 levels over time in each patient after ABOi LDLT. The difference in outcomes following LT according to the FcγR SNP type for rituximab was unclear. Further studies with larger sample sizes are needed to confirm the effect of FcγR SNPs on rituximab therapy.